Journal: Lancet (London, England)

Article Title: Planned early delivery or expectant management for late preterm pre-eclampsia (PHOENIX): a randomised controlled trial

doi: 10.1016/S0140-6736(19)31963-4

Figure Lengend Snippet: Maternal demographic and pregnancy characteristics at baseline and randomisation

Article Snippet: Randomisation was managed via a secure web-based randomisation program provided by MedSciNet.

Techniques:

Journal: Trials

Article Title: Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial)

doi: 10.1186/s13063-018-3150-1

Figure Lengend Snippet: Schedule of participant enrolment, interventions and assessments in the trial. PARCA-R Parent Report of Cognitive Abilities, Revised, SAE serious adverse event. 1 Screening to be conducted of all women suspected of being eligible for the study. 2 Delivery to be commenced within 48 hours of randomisation for women randomised to the planned delivery group. 3 Eligibility for study to be assessed from blood pressure recorded at the time the diagnosis of pre-eclampsia. 4 Blood systolic pressure reading within the 48 hours prior to randomisation to be recorded. 5 Highest systolic blood pressure recorded between randomisation and delivery to be recorded. 6 Highest systolic blood pressure recorded between delivery and discharge to be recorded. 7 Haematology and/or Biochemistry results that contributed to diagnosis of pre-eclampsia to be recorded. 8 The most recent Haematology and/or Biochemistry results prior to randomisation to be recorded. 9 Abnormal Haematology/ Biochemistry results from randomisation to discharge to be recorded at discharge. 10 Serious Adverse Events (SAEs) to be recorded from randomisation to post-natal discharge. Only unexpected SAEs to be reported. 11 Brief details of anti-hypertensive and medication for induction will be recorded; all other concomitant medication will only be recorded in the event that an unexpected Serious Adverse Event is reported. 12 EQ-5D-5L to be given to the participant to complete immediately after randomisation

Article Snippet: Randomisation will be managed via a secure web-based randomisation facility hosted by MedSciNet with a telephone back-up available at all times.

Techniques: Biomarker Discovery

Journal: Frontiers in Pharmacology

Article Title: Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat

doi: 10.3389/fphar.2021.658079

Figure Lengend Snippet: The risk of bias of included trials (Authors judgment/Evidence for judgment).

Article Snippet: (NCT02952092) , Low risk/By a web-based randomization system (EPS corporation, tokyo, Japan) , Low risk/Dynamic allocation was conducted using a biased-coin minimization approach , Low risk/Double blind study , Low risk/Double blind study , Low risk/All dropped-out patients have been reported , Low risk/Information for this study available from Clincialtrials.gov , outcomes reported as planned in Clinicaltrials.gov.

Techniques: Sequencing, Capsules

Journal: Bja Open

Article Title: A protocol for a pilot study to assess the feasibility of a randomised clinical trial of perioperative intravenous lidocaine on colorectal cancer outcome after surgery (FLICOR trial)

doi: 10.1016/j.bjao.2023.100138

Figure Lengend Snippet: A full schedule of trial procedures from screening to the end of study follow-up. 5Q-5D-5L, EuroQol-5 Dimension-5 Level; CEA, carcinoembryonic antigen; FACT-C, Functional Assessment of Cancer Therapy – Colorectal cancer; HRQoL, health-related quality of life.

Article Snippet: Consented participants will be randomly allocated to receive either lidocaine or placebo in a 1:1 ratio on web-based randomisation and Electronic Data Capture (EDC) system called OpenClinica, integrated with the Sealed Envelope system.

Techniques: Functional Assay, Pregnancy Test (hCG) Assay, Computed Tomography, Histopathology